HC Wainwright Reaffirms Buy Rating for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $8.00 target price on the stock.

InflaRx Stock Down 0.8 %

IFRX stock traded down $0.01 during mid-day trading on Friday, reaching $1.18. 153,511 shares of the stock traded hands, compared to its average volume of 212,706. The firm has a market capitalization of $79.22 million, a PE ratio of -1.09 and a beta of 1.98. The business has a 50-day moving average of $2.13 and a two-hundred day moving average of $1.93. InflaRx has a 52 week low of $1.15 and a 52 week high of $2.82.

Institutional Trading of InflaRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC bought a new stake in shares of InflaRx in the fourth quarter valued at approximately $28,000. Geode Capital Management LLC increased its position in InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after acquiring an additional 11,900 shares during the period. Commonwealth Equity Services LLC raised its stake in InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after purchasing an additional 19,000 shares during the last quarter. Walleye Capital LLC bought a new stake in InflaRx in the 4th quarter valued at $51,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in InflaRx in the 4th quarter worth $55,000. Institutional investors and hedge funds own 42.39% of the company's stock.

Remove Ads

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.